TP53 and medulloblastoma: Expectedly, both CKα1 agonists (pyrvinium and SSTC3) and CK2 antagonists (CX-4945) have shown significant efficacy in SHH-activated medulloblastoma mouse models, even in the presence of the TP53 mutation which, as previously mentioned, imparts a worse prognosis [66].